Melanotan I

A synthetic linear tridecapeptide analogue of alpha-MSH carrying Nle4 and D-Phe7 substitutions, characterized in receptor structural-biology research.

Molecular Profile

Type
Synthetic peptide (linear tridecapeptide)
Molecular formula
C78H111N21O19
Molecular weight
~1,646.9 g/mol
CAS number
75921-69-6
Amino acids
13
Sequence
Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
Modification
N-terminal acetylation; C-terminal amide; Nle4 and D-Phe7 substitutions.

Mechanism & Target Class

A linear tridecapeptide analogue of alpha-MSH carrying Nle4 and D-Phe7 substitutions, with N-terminal acetylation and a C-terminal amide. It is characterized as a ligand of a Gs-coupled G-protein-coupled receptor; cryo-EM studies of the receptor–Gs complex have resolved the orthosteric binding pocket and described how a peptide of this class occupies the receptor transmembrane bundle. The Nle4 and D-Phe7 substitutions confer protease resistance, and structural studies have examined how these substitutions affect binding geometry within the orthosteric pocket. The molecule retains the conserved His-Phe-Arg-Trp sequence motif central to its receptor-binding geometry.

Storage & Handling

Lyophilized
-20°C, protected from light and moisture; stable long term.
Handling
Avoid freeze-thaw; protect from light; aqueous solution stored cold.

Primary Database

PubChem CID 16164658 ↗

References (21)

  1. Reviews

    1

    Polańska A, et al. (2024). Postepy Dermatol Alergol

    DOI: 10.5114/ada.2024.138818PubMed 38784937

  2. 2

    Lyseng-Williamson KA (2016). Am J Clin Dermatol

    DOI: 10.1007/s40257-016-0184-6PubMed 26979527

  3. 3

    Wolf Horrell EM, Boulanger MC, D'Orazio JA (2016). Front Genet

    DOI: 10.3389/fgene.2016.00095PubMed 27303435

  4. 4

    Herraiz C, et al. (2017). Biochim Biophys Acta Mol Basis Dis

    DOI: 10.1016/j.bbadis.2017.02.027PubMed 28259754

  5. 5

    Wu J, Cotliar R (2021). J Drugs Dermatol

    DOI: 10.36849/JDD.2021.5526

  6. Clinical

    6

    Langendonk JG, et al. (2015). N Engl J Med

    DOI: 10.1056/NEJMoa1411481PubMed 26132941

  7. 7

    Lim HW, et al. (2014). JAMA Dermatol

    DOI: 10.1001/jamadermatol.2014.1875PubMed 25230094

  8. 8

    Biolcati G, et al. (2015). Br J Dermatol

    DOI: 10.1111/bjd.13598PubMed 25494545

  9. 9

    Haylett AK, et al. (2011). Br J Dermatol

    DOI: 10.1111/j.1365-2133.2010.10104.xPubMed 20969564

  10. 10

    Barman-Aksozen J, et al. (2020). Orphanet J Rare Dis

    DOI: 10.1186/s13023-020-01505-6PubMed 32811524

  11. 11

    Wensink D, et al. (2020). JAMA Dermatol

    DOI: 10.1001/jamadermatol.2020.0352PubMed 32186677

  12. 12

    Lengweiler S, et al. (2015). Skin Pharmacol Physiol

    DOI: 10.1159/000362174PubMed 25402764

  13. 13

    Bohm M, Ehrchen J, Luger TA (2014). J Eur Acad Dermatol Venereol

    DOI: 10.1111/j.1468-3083.2012.04658.xPubMed 22845050

  14. 14

    Biolcati G, et al. (2013). Clin Exp Dermatol

    DOI: 10.1111/ced.12203PubMed 24256215

  15. 15

    Grimes PE, et al. (2013). JAMA Dermatol

    DOI: 10.1001/2013.jamadermatol.386PubMed 23407924

  16. 16

    Toh JJH, et al. (2020). J Am Acad Dermatol

    DOI: 10.1016/j.jaad.2020.01.035PubMed 31987791

  17. 17

    Leaf RK, et al. (2024). Life (Basel)

    DOI: 10.3390/life14060689PubMed 38929673

  18. 18

    Minder AE, et al. (2023). Life (Basel)

    DOI: 10.3390/life13041066PubMed 37109595

  19. Primary research

    19

    Peake M, Rutter K, Griffin L, et al. (2024). J Invest Dermatol

    DOI: 10.1016/j.jid.2024.10.472

  20. 20

    Ma S, Chen Y, Dai A, et al. (2021). Cell Res

    DOI: 10.1038/s41422-021-00557-yPubMed 34453129

  21. 21

    Minder EI, Barman-Aksoezen J, Schneider-Yin X (2017). Clin Pharmacokinet

    DOI: 10.1007/s40262-016-0501-5PubMed 28063031